Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

doi:10.1200/JCO.2014.60.4165

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2015

Meric-Bernstam Funda, Brusco Lauren, Shaw Kenna, Horombe Chacha, Kopetz Scott, Davies Michael A, Routbort Mark, Piha-Paul Sarina A, Janku Filip, Ueno Naoto, Hong David, De Groot John, Ravi Vinod, Li Yisheng, Luthra Raja, Patel Keyur, Broaddus Russell, Mendelsohn John, Mills Gordon B

Abstract excerpt

PURPOSE: We report the experience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testing protocol, including the frequency of actionable alterations across tumor types, subsequent enrollment onto clinical trials, and the challenges for trial enrollment. PATIENTS AND METHODS: Standardized hotspot mutation analysis was performed in 2,000 patients, using either an 11-gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Feasibility Studies

Share to Patient Selection

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Source

Open in PubMed Open full text

Identifiers

PMID: 26014291
DOI: 10.1200/JCO.2014.60.4165
PMCID: PMC4550690

Genes

AKT1
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.PMID 26014291Read ↗

Clinical next generation sequencing to identify actionable aberrations in a phase I program.Semantic proximity Read ↗

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Semantic proximity Read ↗

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.Semantic proximity Read ↗

Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.Semantic proximity Read ↗

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.Semantic proximity Read ↗

Clinical Use of Precision Oncology Decision SupportSemantic proximity Read ↗

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Semantic proximity Read ↗

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced CancersSemantic proximity Read ↗

Designing Transformative Clinical Trials in the Cancer Genome EraSemantic proximity Read ↗

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersSemantic proximity Read ↗

Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical TrialsSemantic proximity Read ↗

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.